Navigation Links
Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
Date:6/9/2009

Leiden, The Netherlands, June 09, 2009 / b3c newswire / - Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna’s viral gene delivery platform SVac. Under this agreement, TNO will develop novel methods for the manufacture, formulation and testing of viral gene delivery systems such as the SVac platform of Amarna. The collaboration is partly supported by a co-financing initiative aimed at developing innovative technologies.

“We are very pleased to work with TNO”, said Ben van Leent, CEO of Amarna Therapeutics. “We have developed a revolutionary novel viral gene delivery vector platform technology SVac for producing human therapeutics that have the potential to save lives and improve the quality of life for millions of people worldwide that are suffering from life-threatening or severe chronic diseases. The technology is now available to address the major diseases of our time including genetic disorders, autoimmune diseases, allergies and cancer. Amarna Therapeutics acts at the forefront of the therapeutic vaccination and gene therapy markets. Both markets are rapidly growing to reach an estimated 40 billion Euro’s in 2015. I’m convinced that the therapeutics in our pipeline all have blockbuster potential. The partnership with TNO enables us to initiate the first time in man clinical trials with one of our lead therapeutics in 2010.”

“The partnership between TNO and Amarna allows us to expand our pre-clinical development services into the extremely important therapeutic area of viral vector and gene delivery technologies and is yet another important step in our establishment of a fully integrated and highly innovative package of biopharmaceutical development capabilities” says Menzo Havenga, Managing Director of Biosciences at TNO.


About Amarna Therapeutics
Amarna Therapeutics B.V. is a Biotechnology company that develops therapeutic vaccinations to treat immunity-associated diseases including autoimmune diseases, allergies and cancer and gene therapies to treat genetic disorders. The base of Amarna’s therapeutics is the SVac viral gene delivery vector platform, which provides sensational characters unheard of in the Pharma arena, creating opportunities to serve markets with enormous potential due to clinical unmet needs.

About SVac
Our SVac viral gene delivery vector platform has a number of unique properties compared to other viral gene delivery vectors such as lentiviral, poxviral, alphaviral, adenoviral and adeno-associated virus (AAV) vector systems. SVac is non-immunogenic in humans, highly stable, safe to use and can be cost effectively produced in large amounts in a proprietary producer cell line denoted SuperVero. Moreover, the vector has extensively been tested for safety in model animals. The SuperVero cell line has been qualified and tested using Quality Control (QC) assays and its use for manufacturing clinical trial material has been validated. The whole vector production process is similar to the current manufacturing processes of the polio, rabies and influenza virus vaccines in which a master seed virus is seeded to producer cells in large fermentors. Because of its immunological inertia in man SVac is the only vector system known that is suitable for for treating genetic disorders and immunity associated diseases.

About TNO
TNO is a prominent, independent knowledge company whose expertise and research contribute significantly to the competitiveness of businesses and organizations, to the economy and to the quality of life as a whole. Its versatility and capacity to integrate a broad diversity of sciences and technologies makes TNO unique. TNO employs about 4300 professionals in five core areas: TNO Quality of Life, TNO Defense, Security and Safety, TNO Science and Industry, TNO Built Environment and Geosciences, TNO Information and Communication Technology.
Within biopharmaceutical development, TNO’s mission is to optimize and accelerate the transition of human therapeutics from discovery to the clinic. TNO strives towards this goal by establishing innovative product development and manufacturing technologies and applying them in a fully integrated package of pre-clinical development services.


For further information please contact:


For Amarna Therapeutics:

Ben van Leent
T: +31 71 3322192
M: +31 6 47566999
F: +31 71 3322195
E: ben.vanleent@amarnatherapeutics.com
W: www.amarnatherapeutics.com

For TNO:
Heather Wagner
T: +31 (30) 6944615
M: +31 (6) 23296045
E: heather.wagner@tno.nl
W: www.tno.nl/pharma


'/>"/>
b3c newswire

Related biology news :

1. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
2. NIH announces new program to develop therapeutics for rare and neglected diseases
3. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
4. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
5. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
6. A novel target for therapeutics against Staph infection
7. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
8. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
9. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
10. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
11. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology: